| Ytd | -1.76% | |
| 1y | 22.16% |
| Open | 292.52 | Prev Close | 290.74 | Low | 291.87 | High | 300.16 | Mkt Cap | 31.02B |
| Vol | 86.07K | Avg Vol | 253.18K | EPS | 4.42 | P/E | 67.64 | Forward P/E | 29.93 |
| Beta | 0.49 | Short Ratio | 3.29 | Inst. Own | 32.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 290.02 | 200-d Avg | 316.24 | 1yr Est | 412.35 |
ONC News
Citizens analyst Reni J. Benjamin reiterates BeOne Medicines (NASDAQ:ONC) with a Market Outperfor
BeOne Medicines reported positive Phase 3 BRUKINSA data in mantle cell lymphoma, reducing progressio
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today anno
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
As previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. (the "
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today anno
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra
BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflec
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and
BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO
BeOne Medicines NASDAQ: ONC used an investor event at ASCO to outline what executives described as a
Summit Therapeutics' new ivonescimab trial results showed a survival benefit in lung cancer and
Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with Ch
BeOne Medicines Ltd. ("BeOne") (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology c
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HK
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today annou
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HK
The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval to BeOne Medic
FDA grants accelerated approval to BeOne's BEQALZI for relapsed mantle cell lymphoma after prior
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HK
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and
Guggenheim analyst Michael Schmidt maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises t
Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises
Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and ra
BeOne Medicines AG (ONC) Q1 2026 Earnings Call Transcript
BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.200 billion-$6.400 billion to $6.30
BeiGene (NASDAQ:ONC) reported quarterly earnings of $3.24 per share which beat the analyst consensus
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160;
Pre-Market Stock Futures: Futures are trading lower as we start off the new week, as oil surges high
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160;
Wolfe Research analyst Kalpit Patel initiates coverage on BeOne Medicines (NASDAQ:ONC) with a Out
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai
Guggenheim analyst Michael Schmidt maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises t
Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises
